[1] Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet, 2013; 381, 1987−2015. doi:  10.1016/S0140-6736(13)61097-1
[2] Moran A, Gu D, Zhao D, et al. Future cardiovascular disease in China: Markov model and risk factor scenario projections from the coronary heart disease policy model—China. Circ Cardiovasc Qual Outcomes, 2010; 3, 243−52. doi:  10.1161/CIRCOUTCOMES.109.910711
[3] Connection, Communication and Hearts. The development and achievement of interventional cardiology in China. http://www.ccheart.com.cn/news/12193/. [2014-6-19]. (In Chinese)
[4] Zheng X, Bai XK, Huo XQ, et al. Percutaneous coronary intervention in eastern urban China: 2001-2011. Zhonghua Yi Xue Za Zhi, 2016; 96, 1863.
[5] National Center for Cardiovascular Diseases, China. Report on cardiovascular disease in China 2014. Beijing: Encyclopedia of China Publishing House, 2015.
[6] National Quality Forum: Candidate hospital care additional priorities: 2007 performance measure. Washington, DC: National Quality Forum; 2007.
[7] Centers for Medicare and Medicaid Services: Application of incentives to reduce avoidable readmissions to hospitals. Centers for Medicare and Medicaid Services. Application of incentives to reduce avoidable readmissions to hospitals. Fed Regist, 2008; 73, 23673−5.
[8] Meadows ES, Bae JP, Zagar A, et al. Rehospitalization following percutaneous coronary intervention for commercially insured patients with acute coronary syndrome: a retrospective analysis. Bmc Research Notes, 2012; 5, 1−8.
[9] Curtis JP, Schreiner G, Wang Y, et al. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients. J Am Coll Cardiol, 2009; 54, 908−10. doi:  10.1016/j.jacc.2009.05.037
[10] Arnold SV, Smolderen KG, Kennedy KF, et al. Risk factors for rehospitalization for acute coronary syndromes and unplanned revascularization following acute myocardial infarction. J Am Heart Assoc, 2015; 4.
[11] Wasfy JH, Strom JB, O'Brien C, et al. Causes of short-term readmission after percutaneous coronary intervention. South China J Cardiol, 2014; 67, 64−5.
[12] Benzer W, Philippi A, Hoefer S, et al. Health-related quality of life predicts unplanned rehospitalization following coronary revascularization. Herz, 2016; 41, 138−43.
[13] Song Y, Gao Z, Tang X, et al. Impact of residual SYNTAX score on clinical outcomes after incomplete revascularisation percutaneous coronary intervention: a large single-centre study. EuroIntervention, 2017; 13, 1185−93. doi:  10.4244/EIJ-D-17-00132
[14] Zheng X, Curtis JP, Hu S, et al. China PEACE Collaborative Group. Coronary catheterization and percutaneous coronary intervention in china: 10-year results from the China PEACE-Retrospective CathPCI study. JAMA Intern Med, 2016; 176, 512−21. doi:  10.1001/jamainternmed.2016.0166
[15] Liu R, Gao Z, Chen J, et al. Comparison between imported versus domestic drug-eluting stents in China: a large single-center data. J Interven Cardiol, 2017; 30, 338−46. doi:  10.1111/joic.12402
[16] Przybysz-Zdunek B, Ploch M, Pluta W, et al. All-cause readmission and repeat revascularization after percutaneous coronary intervention. Cardiol J, 2012; 19, 174−9. doi:  10.5603/CJ.2012.0030
[17] He C, Ma YL, Wang CS, et al. Long-term outcomes of primary percutaneous coronary intervention with second-generation drug-eluting stents in sT-elevation myocardial infarction patients caused by very late stent thrombosis. Chin Med J, 2017; 130, 929−35. doi:  10.4103/0366-6999.204111
[18] Rodrigues CG, Moraes MA, Sauer JM, et al. Nursing diagnosis of activity intolerance: clinical validation in patients with refractory angina. Int J Nurs Terminol Classif, 2011; 3, 117−22.
[19] Yiu KH, Pong V, Siu CW, et al. Long-term oral nitrate therapy is associated with adverse outcome in diabetic patients following elective percutaneous coronary intervention. Cardiovascu Diabetol, 2011; 10, 1−6. doi:  10.1186/1475-2840-10-1
[20] Kossovsky MP, Keller PF, Mach F, et al. Fondaparinux versus enoxaparin in the management of acute coronary syndromes in Switzerland: A cost comparison analysis. Swiss Med Wkly, 2012; 142, w13536.
[21] Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA, 2003; 289, 331−42. doi:  10.1001/jama.289.3.331
[22] Navarese EP, De Luca G, Castriota F, et al. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost, 2011; 9, 1902−15.
[23] Hawranek M, Desperak P, Gąsior P, et al. Early and long-term outcomes of complete revascularization with percutaneous coronary intervention in patients with multivessel coronary artery disease presenting with non-ST-segment elevation acute coronary syndromes. Adv Interv Cardiol, 2018; 14, 32−41.
[24] Généreux P, Palmerini T, Caixeta A, et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (synergy between PCI with Taxus and cardiac surgery) score. J Am Col Cardiol, 2012; 59, 2165−74.
[25] Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2018; 39, 119−77.
[26] Hani Jneid, Jeffrey L Anderson, R Scott Wright, et al. ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2012; 126, 875−910. doi:  10.1161/CIR.0b013e318256f1e0
[27] Calle EE, Thun MJ, Petrelli JM, et al. Body mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med, 1999; 341, 1097−105. doi:  10.1056/NEJM199910073411501
[28] Wilson PW, D’Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med, 2002; 162, 1867−72. doi:  10.1001/archinte.162.16.1867
[29] Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA, 1999; 282, 1530−8.
[30] Powell BD, Lennon RJ, Lerman A, et al. Association of body mass index with outcome after percutaneous coronary intervention. Am J Cardiol, 2003; 91, 472−76.
[31] Wang H, Gao Z, Zhao X, et al. Association of body mass index with mortality in Chinese patients after percutaneous coronary intervention: a large single- center data. Cardiovasc Ther, 2017; 35, e12271.
[32] Santaniemi M, Ukkola O, Malo E, et al. Metabolic syndrome in the prediction of cardiovascular events: the potential additive role of hsCRP and adiponectin. Eur J Prev Cardiol, 2014; 21, 1242−48. doi:  10.1177/2047487313494028
[33] Shibata R, Ouchi N, Kikuchi R, et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis, 2011; 219, 811−14.
[34] Malyszko J, Malyszko JS, Pawlak K, et al. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci, 2008; 53, 32−6.
[35] Siudak Z, Tokarek T, Dziewierz A, et al. Reduced periprocedural mortality and bleeding rates of radial approach in ST-segment elevation myocardial infarction. Propensity score analysis of data from the ORPKI Polish National Registry. EuroIntervention, 2017; 13, 843−50.
[36] Tokarek T, Dziewierz A, Plens K, et al. Radial approach expertise and clinical outcomes of percutanous coronary interventions performed using femoral approach. J Clin Med, 2019; 8, 1484.
[37] Sheiban I, Villata G, Bollati M, et al. Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V). Vasc Health Risk Manag, 2008; 4, 31−8.
[38] Fox K, Garcia MA, Ardissino D, et al. Task force on the management of stable angina pectoris of the European society of cardiology; ESC Committee for practice guidelines (CPG). Guidelines on the management of stable angina pectoris: Executive summary: the task force on the management of stable angina pectoris of the European Society of Cardiology. Eur Heart J, 2006; 27, 1341−81. doi:  10.1093/eurheartj/ehl001
[39] Weintraub WS, Spertus JA, Kolm P, et al. COURAGE Trial Research Group, Mancini GB. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med, 2008; 359, 677−87.
[40] Mitsutake Y, Ueno T, Yokoyama S, et al. Coronary endothelial dysfunction distal to stent of first-generation drug-eluting stents. JACC Cardiovasc Interv, 2012; 5, 966−73.
[41] Pendyala LK, Yin X, Li J, et al. The first-generation drug-eluting stents and coronary endothelial dysfunction. JACC Cardiovasc Interv, 2009; 2, 1169−77.
[42] Wang XZ, Xu K, Li Y, et al. Comparison of the efficacy of drug-eluting stents versus bare-metal stents for the treatment of left main coronary artery disease. Chin Med J, 2015; 128, 721−6. doi:  10.4103/0366-6999.152460
[43] Yu XP, Wu CY, Ren XJ, et al. Very long-term outcomes and predictors of percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting for patients with unprotected left main coronary artery disease. Chin Med J, 2016; 129, 763−70. doi:  10.4103/0366-6999.178968
[44] Windecker S, Stortecky S, Stefanini GG, et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: Network meta-analysis. BMJ, 2014; 348, g3859. doi:  10.1136/bmj.g3859